# Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

> **NCT02502786** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 46 (actual)

## Conditions studied

- Recurrent Osteosarcoma

## Interventions

- **BIOLOGICAL:** humanized anti-GD2 antibody
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT02502786
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-07
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02502786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02502786, "Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02502786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*